Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.39 |
| ▸ | CA1 | P00915 | 12/20 | 0.36 |
| ▸ | CA9 | Q16790 | 12/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA3 | P07451 | 3/20 | 0.36 |
| ▸ | CA4 | P22748 | 3/20 | 0.36 |
| ▸ | CA6 | P23280 | 3/20 | 0.36 |
| ▸ | CA5A | P35218 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27625464 | 1.00 | CA2 (0.39) | CA2CA1CA9CA12CA3 | |
| SCHEMBL27607145 | 1.00 | CA2 (0.39) | CA2CA1CA9CA12CA3 | |
| SCHEMBL27607021 | 1.00 | CA2 (0.39) | CA2CA1CA9CA12CA3 | |
| SCHEMBL5200383 | 1.00 | CA2 (0.39) | CA2CA1CA9CA12CA3 | |
| SCHEMBL195680 | 0.97 | — | — | |
| SCHEMBL483134 | 0.88 | — | — | |
| SCHEMBL30041571 | 0.85 | CA2 (0.48) | CA2CA1CA9CA12CA3 | |
| SCHEMBL8069056 | 0.85 | CA2 (0.48) | CA2CA1CA9CA12CA3 | |
| SCHEMBL11147913 | 0.85 | CA2 (0.48) | CA2CA1CA9CA12CA3 | |
| SCHEMBL10798852 | 0.85 | CA2 (0.48) | CA2CA1CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| CN-101233108-A | Cyclic amine derivative having substituted alkyl group | DAIICHI SANKYO CO LTD (JP) | 2008-07-30 | — | — | CN | disclosed |
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
| CN-100341947-C | Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides | BASF AG (DE) | 2007-10-10 | — | — | CN | disclosed |
| CN-1649967-A | Method for the production of perylen-3,4:9,10-tetracarboxylic acid diimides and perylen-3,4:9,10-tetracarboxylic acid dianhydride and naphtalene-1,8-dicarboxylimides | BASF AG (DE) | 2005-08-03 | — | — | CN | disclosed |
| EP-0215435-B1 | 2-OXA-ISOCEPHEM COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-4831026-A | ANTIBIOTICS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| EP-0215435-A1 | 2-Oxa-isocephem compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | CBR3, CNR1, C3AR1 | CA2 610/4885CA1 495/4885CA9 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.